Consistent with rationalizations on genes with both oncogenic and tumor-suppressor functions by Shen et al. [38], it is also probable that the function-altering mutations in FAT1 are the main driving force in the FAT1-facilitated oncogenesis and cisplatin resistance in OSCC documented herein. This evidence concerns the gene FAT1 and neoplasm.